GoldBamboo.com - Knowledge is strong medicine
  

Darbepoetin alfa in Treating Anemia in Patients With Cancer Who Are Receiving Chemotherapy - Article


  Not Signed In - Sign In / Register








Anemia

General anemia 



Clinical Trial: Darbepoetin alfa in Treating Anemia in Patients With Cancer Who Are Receiving Chemotherapy

This study is no longer recruiting patients.

Sponsors and Collaborators: National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
Information provided by: National Cancer Institute (NCI)

Purpose

RATIONALE: Darbepoetin alfa may stimulate red blood cell production and may be effective in treating anemia in patients who are receiving chemotherapy. PURPOSE: Randomized phase II trial to determine the effectiveness of darbepoetin alfa in treating anemia in patients who are receiving chemotherapy for cancer.

Condition Treatment or Intervention Phase
Anemia
unspecified adult solid tumor, protocol specific
 Procedure: supportive care
 Drug: hematologic toxicity attenuation
 Behavior: supportive care/therapy
 Drug: darbepoetin alfa
Phase II

MedlinePlus related topics:  Anemia;   Cancer;   Cancer Alternative Therapy

Study Type: Interventional
Study Design: Educational/Counseling/Training

Official Title: Phase II Randomized Study of Darbepoetin alfa for the Treatment of Anemia in Patients With Nonmyeloid Malignancies Receiving Multiple Courses of Chemotherapy

Further Study Details: 

OBJECTIVES: I. Compare the efficacy of darbepotein alfa administered on the same day as chemotherapy vs an alternate time to chemotherapy administration for the treatment of anemia in patients with nonmyeloid malignancies receiving multiple courses of chemotherapy. II. Determine the safety of this drug in these patients. III. Determine the pharmacokinetic profile of this drug in these patients.

PROTOCOL OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to screening hemoglobin (less than 10.0 g/dL vs 10.0-11.0 g/dL) and participating center. Patients are randomized to 1 of 2 treatment arms. Arm I: Patients receive darbepoetin alfa subcutaneously (SC) on day 15 of each chemotherapy course. Arm II: Patients receive darbepoetin alfa SC on day 1 of each chemotherapy course. In both arms, treatment repeats every 3 weeks for up to 5 courses in the absence of unacceptable toxicity or treatment failure.

PROJECTED ACCRUAL: A total of 80 patients (40 per arm) will be accrued for this study within 8 months.

Eligibility

Ages Eligible for Study:  18 Years and above

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Diagnosis of a nonmyeloid malignancy

Cancer- or chemotherapy-related anemia

  • Hemoglobin 9.0-11.0 g/dL

Currently receiving chemotherapy on a 3-week course schedule

  • Myelosuppressive chemotherapy must not be administered on course days 9-21
  • At least 2 additional courses of chemotherapy planned

No other primary hematologic disorder that would cause anemia (e.g., sickle cell anemia)

--Prior/Concurrent Therapy--

Biologic therapy:

  • At least 4 weeks since prior epoetin alfa or darbepoetin alfa
  • No other concurrent epoetin alfas

Chemotherapy: See Disease Characteristics

Endocrine therapy: Not specified

Radiotherapy: Concurrent radiotherapy allowed

Surgery: Not specified

Other:

--Patient Characteristics--

Age: 18 and over

Performance status: ECOG 0-2

Life expectancy: Not specified

Hematopoietic: See Disease Characteristics

Hepatic: Bilirubin less than 2 times upper limit of normal (ULN)

Renal: Creatinine less than 2 times ULN

Cardiovascular:

  • No uncontrolled angina
  • No congestive heart failure
  • No New York Heart Association class III-IV cardiac disease
  • No uncontrolled hypertension
  • No cardiac arrhythmia
  • No other unstable or uncontrolled cardiac disease or condition

Other:

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • HIV negative
  • No seizure disorder
  • No clinically significant inflammatory disease
  • No hypersensitivity to recombinant mammalian-derived products

Location Information

Study chairs or principal investigators

John A. Glaspy,  Study Chair,  Jonsson Comprehensive Cancer Center   

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers:  CDR0000069366; UCLA-0111006; NCI-G02-2071; AMGEN-20010162
Record last reviewed:  August 2003
Last Updated:  October 13, 2004
Record first received:  June 6, 2002
ClinicalTrials.gov Identifier:  NCT00039247
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Resources



[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Take control over your directory listings...INSTANTLY

Every day, thousands of users find businesses like yours in the GoldBamboo directory.

Limited Time Offer!!!

For only $30 a year, a savings of 70% off our standard rate:

  • Edit your listing (whenever you want!)
  • Link to your website
  • Choose which categories you are listed in
  • Describe your services

The process will take only a few minutes and consists of 3 easy steps:

1. Register     >     2. Edit Listings     >     3. Publish

Your Company
your street
yourtown, YS 12345
888-888-8888



No Thanks

Popular Treatments

Acne Treatment ADHD Treatment Allergy Treatment Alzheimer's Treatment
Anemia Treatment Arthritis Treatment Asthma Treatment Bipolar Disorder Treatment
Bird Flu Treatment Bladder Cancer Treatment Bladder Control Treatment Blood Pressure Treatment
Brain Tumor Treatment Breast Cancer Treatment Bronchitis Treatment Cancer Treatment
Cancer Alternative Treatment Cataract Treatment Cirrhosis Treatment Colitis Treatment
Colon Cancer Treatment Common Cold Treatment Conjunctivitis Treatment Constipation Treatment
Crohn's Disease Treatment Cystic Fibrosis Treatment Depression Treatment Dermatitis Treatment
Diabetes Treatment Edema Treatment Epilepsy Treatment Erectile Dysfunction Treatment
Fibromyalgia Treatment GERD Treatment Glaucoma Treatment Gout Treatment
Hay Fever Treatment Headache Treatment Heart Disease Treatment Hepatitis Treatment
High Blood Pressure Treatment High Cholesterol Treatment Hives Treatment Hypertension Treatment
Hypoglycemia Treatment IBS Treatment Impotence Treatment Indigestion Treatment
Infertility Treatment Influenza Treatment Insomnia Treatment Lactose Intolerance Treatment
Leukemia Treatment Lung Cancer Treatment Lyme Disease Treatment Macular Degeneration Treatment
Menopause Treatment Migraine Treatment Osteoarthritis Treatment Osteoporosis Treatment
Pancreatic Cancer Treatment PMS Treatment Pneumonia Treatment Prostate Diseases Treatment
Restless Leg Treatment Rheumatoid Arthritis Treatment Sepsis Treatment Sinusitis Treatment
Skin Cancer Treatment Sleep Apnea Treatment Snoring Treatment Stroke Treatment
Testicular Cancer Treatment
GoldBambooTM

Your Integrative Health and Wellness Resource for Anemia.

July 23, 2014



Page Updated: October 15, 2009
Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.

Home | About Us | Link To Us | Feedback | Disclaimer | Privacy Policy | Terms of Use

Copyright © 2004-2014 - Anaconda Partners LLC - All rights reserved.